Off-label use of rituximab in dermatology: pemphigus treatment

Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Bomm, Lislaine, Fracaroli, Tainá Scalfoni, Sodré, João Luz, Bressan, Aline, Gripp, Alexandre Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2013
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760958/
https://www.ncbi.nlm.nih.gov/pubmed/24068154
http://dx.doi.org/10.1590/abd1806-4841.20131905
Descripción
Sumario:Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris and two cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m2 once a week for 4 weeks, and that responded well to treatment.

Ejemplares similares